



## (51) International Patent Classification:

C07K 16/28 (2006.01) G01N 33/577 (2006.01)

C12N 5/20 (2006.01) C12N 15/85 (2006.01)

A61P 35/00 (2006.01)

## (21) International Application Number:

PCT/CN2023/080090

## (22) International Filing Date:

07 March 2023 (07.03.2023)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

PCT/CN2022/079943

09 March 2022 (09.03.2022) CN

PCT/CN2022/122679

29 September 2022 (29.09.2022) CN

PCT/CN2023/077693

22 February 2023 (22.02.2023) CN

Changning District, Shanghai 200051 (CN). **REN, Yi-jing**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN). **LI, Teng-teng**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN). **CHEN, Peng**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN). **HOU, Bing**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN). **SHAN, Bo**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN). **MEI, Jay**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN).

(74) **Agent: JUN HE LAW OFFICES**; 20/F, China Resources Building 8 Jianguomenbei Avenue, Dongcheng District, Beijing 100005 (CN).

(71) **Applicant (for CN only): ANTENGNE (HANGZHOU) BIOLOGICS CO., LTD.** [CN/CN]; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN).

(71) **Applicant (for all designated States except CN): ANTENGNE BIOLOGICS LIMITED** [CN/CN]; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District, Shanghai 200051 (CN).

(72) **Inventors: YUWEN, Hui**; Suite 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road,

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** NOVEL ANTI-CD3 ANTIBODIES AND USES THEREOF




Fig. 18

(57) **Abstract:** Provided are anti-CD3 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical composition comprising the same and the uses thereof.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))